De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen

13-Sep-2007

De Novo Pharmaceuticals Ltd. announced today that it has entered into a drug discovery partnership agreement with Achaogen whereby De Novo will apply its novel molecular structure generating drug discovery platform targeting pathogenic bacteria. Financial terms of the agreement were not disclosed.

"We are very pleased to be working with Achaogen- a leader in the fight against drug-resistant bacteria," said Philip Dean, Ph.D., CSO at De Novo. "Using SkelGen, we will be designing for Achaogen new chemical classes of inhibitors focused on an important drug-resistant bacterial target", he added.

"We are pleased to be working with De Novo to expand our lead optimization program, and to help us develop cutting-edge therapeutics that will speed us towards our goal of providing therapies to treat unmet clinical needs caused by multi-drug resistant bacterial infections," said Phillip Patten, Ph.D., Senior Vice President, Biology at Achaogen.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances